Arbutus Biopharma Corporation ABUS Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $23.71M-36.1% | $18.01M-50.4% | $22.41M-29.6% | $37.41M-40.4% | $37.08M-14.0% | ||
| $71.52M-5.4% | $73.46M-14.9% | $71.29M-25.7% | $60.68M-23.4% | $75.63M-12.2% | ||
| $178.74M+15,022% | $0-100% | $905K-43.7% | $1.03M-42.0% | $1.18M-44.7% | ||
| $1.73M-40.7% | $1.54M-32.7% | $2.84M-16.0% | $4.01M-10.3% | $2.92M-35.0% | ||
| $300K+50.0% | $300K0.0% | $300K0.0% | $100K-66.7% | $200K-66.7% | ||
| $277.01M+137% | $94.46M-25.8% | $97.44M-26.6% | $103.12M-30.4% | $116.81M-14.0% | ||
| $22K-86.9% | $32K-99.0% | $137K-96.1% | $148K-96.4% | $168K-96.2% | ||
| $224K-98.3% | $213K-98.4% | $13.35M+5.4% | $13.32M+5.6% | $13.33M+8.7% | ||
| $131K+285% | $130K+282% | $131K— | $0— | $34K— | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $277.16M+137% | $94.62M-28.2% | $97.71M-30.4% | $103.27M-35.5% | $117.01M-22.1% | ||
| $1.46M-34.7% | $1.17M-49.4% | $1.01M-56.3% | $1.32M-50.2% | $2.24M-40.2% | ||
| $631K+12.1% | $547K+13.3% | $531K+13.5% | $514K+13.5% | $563K+12.2% | ||
| $5.11M-73.7% | $6.01M-61.5% | $5.18M-72.6% | $5.02M-77.8% | $19.43M-4.3% | ||
| $0— | —— | $0— | $0— | $0— | ||
| $0-100% | $199K-75.3% | $391K-60.0% | $575K-49.7% | $626K-47.0% | ||
| $16.99M-55.1% | $18.04M-47.5% | $20.31M-39.5% | $20.29M-46.0% | $37.85M+6.2% | ||
| $1.44B+2.0% | $1.42B+0.8% | $1.42B+0.8% | $1.42B+1.0% | $1.42B+2.8% | ||
| $74.26M-9.5% | $83.32M+1.5% | $83.29M+2.3% | $82.63M+1.1% | $82.09M+2.3% | ||
| -$1.21B+11.7% | -$1.38B-2.5% | -$1.38B-3.2% | -$1.37B-4.1% | -$1.37B-5.9% | ||
| -$48.2M-0.1% | -$48.1M+0.1% | -$48.13M-0.1% | -$48.19M+0.3% | -$48.17M+0.4% | ||
| $260.18M+229% | $76.58M-21.4% | $77.4M-27.6% | $82.98M-32.2% | $79.16M-30.9% | ||
| $277.16M+137% | $94.62M-28.2% | $97.71M-30.4% | $103.27M-35.5% | $117.01M-22.1% | ||
| $71.53M-5.4% | $73.38M-14.9% | $71.24M— | $60.68M— | $75.61M— | ||
| $71.52M-5.4% | $73.46M-14.9% | $71.29M— | $60.68M— | $75.63M— | ||
| $71.52M-5.4% | $73.46M-14.9% | $71.29M-25.7% | $60.68M-23.4% | $75.63M-12.2% | ||
| $131K+285% | $130K+282% | $131K— | $0— | $34K— | ||
| $71.53M-5.4% | $73.38M-14.9% | $71.24M— | $60.68M— | $75.61M— | ||
| $95.2M-15.5% | —— | $93.7M-28.4% | $98.1M-33.9% | $112.7M-18.3% | ||
| $131K+285% | $130K+282% | $131K— | $0— | $34K— | ||
| $131K+285% | $130K+282% | $131K— | $0— | $34K— | ||
| $4.47M-63.1% | $5.46M-27.8% | $4.65M-38.3% | $4.51M-59.4% | $12.11M+46.8% | ||
| $1.57M-29.8% | $1.08M-7.6% | $443K-37.5% | $352K-82.1% | $2.24M+90.7% | ||
| $245K-95.9% | $640K— | $763K+27.2% | $768K— | $5.97M— | ||
| $8.6M-18.2% | $8.4M-17.9% | $11.05M+32.6% | $10.78M+35.0% | $10.52M+35.3% | ||
| $631K-46.9% | $746K-42.1% | $922K-36.2% | $1.09M-31.8% | $1.19M-29.4% | ||
| 196.9M+2.9% | 192.5M+1.4% | 192M+1.3% | 191.6M+1.5% | 191.5M+6.3% | ||
| 1.2M0.0% | —— | 1.2M0.0% | 1.2M0.0% | 1.2M0.0% | ||
| $1.44B+2.0% | $1.42B+0.8% | $1.42B+0.8% | $1.42B+1.0% | $1.42B+2.8% | ||
| $13K-48.0% | $87K+55.4% | $61K— | $9K— | $25K— | ||
| $23K+360% | $0-100% | $4K— | $11K— | $5K— | ||
| 22+57.1% | 0-100% | 8+14.3% | 20-28.6% | 14-66.7% | ||
| $71.53M-5.4% | $73.38M-14.9% | $71.24M— | $60.68M— | $75.61M— | ||
| $789K+59.7% | $2.16M-36.4% | $2.02M-21.8% | $975K-60.7% | $494K-64.5% | ||
| $1.57M-29.8% | $1.08M-7.6% | $443K-37.5% | $352K-82.1% | $2.24M+90.7% | ||
| $407K-65.3% | $412K-40.4% | $413K-69.8% | $1.09M-72.8% | $1.17M-39.5% | ||
| $23K+360% | $0-100% | $4K— | $11K— | $5K— | ||
| $13K-48.0% | $87K+55.4% | $61K— | $9K— | $25K— | ||
| $71.53M-5.4% | $73.38M-14.9% | $71.24M— | $60.68M— | $75.61M— | ||
| $71.52M-5.4% | $73.46M-14.9% | $71.29M— | $60.68M— | $75.63M— | ||
| $14.49M-45.1% | $10.22M-65.4% | $7.84M— | $30.4M— | $26.38M— | ||
| $196.95M+2.9% | $192.53M+1.4% | $191.95M+1.3% | $191.64M+1.5% | $191.48M+6.3% | ||
| $196.95M+2.9% | $192.53M+1.4% | $191.95M+1.3% | $191.64M+1.5% | $191.48M+6.3% | ||
| $22+57.1% | $0-100% | $8+14.3% | $20-28.6% | $14-66.7% | ||
| $0— | —— | $0— | $0— | $0— | ||
| $3.28M-25.7% | $3.44M-28.7% | $3.68M-30.7% | $3.91M-33.3% | $4.41M-31.1% | ||
| $1.16M0.0% | —— | $1.16M0.0% | $1.16M0.0% | $1.16M0.0% | ||
| $245K-95.9% | $640K— | $763K— | $768K— | $5.97M— | ||
| 20.0% | —— | 20.0% | 20.0% | 20.0% | ||
| 10.0% | —— | 10.0% | 10.0% | 10.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Arbutus Biopharma Corporation's total assets?
- Arbutus Biopharma Corporation (ABUS) holds $277.2M in total assets, up 136.9% year over year.
- How much debt does Arbutus Biopharma Corporation have?
- Arbutus Biopharma Corporation carries $631.0K in total debt against $260.2M of shareholders' equity, a debt-to-equity ratio of 0.00.
- How much cash does Arbutus Biopharma Corporation have?
- Arbutus Biopharma Corporation holds $23.7M in cash and equivalents.
- Can Arbutus Biopharma Corporation cover its short-term obligations?
- Its current ratio is 54.26 — current assets exceed current liabilities.
- Where does Arbutus Biopharma Corporation's balance sheet data come from?
- Every line is extracted from Arbutus Biopharma Corporation's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
